Cytomegalovirus and Epstein-Barr virus infection during daratumumab treatment in patients with multiple myeloma

被引：6

作者：

Li, Shuchan ^{[1
,2
]}

Zheng, Gaofeng ^{[1
,2
]}

He, Jingsong ^{[1
,2
]}

Wu, Wenjun ^{[1
,2
]}

Chen, Qingxiao ^{[1
,2
]}

Yang, Yang ^{[1
,2
]}

He, Donghua ^{[1
,2
]}

Zhao, Yi ^{[1
,2
]}

Han, Xiaoyan ^{[1
,2
,3
]}

Cai, Zhen ^{[1
,2
,3
]}

机构：

[1] Zhejiang Univ, Affiliated Hosp 1, Bone Marrow Transplantat Ctr, Sch Med, Hangzhou, Zhejiang, Peoples R China

[2] Zhejiang Univ, Inst Hematol, Hangzhou, Zhejiang, Peoples R China

[3] Zhejiang Univ, Affiliated Hosp 1, Bone Marrow Transplantat Ctr, Sch Med, 79 Qingchun Rd, Hangzhou, Zhejiang, Peoples R China

来源：

LEUKEMIA & LYMPHOMA | 2023年 / 64卷 / 04期

基金：

中国国家自然科学基金;

关键词：

Multiple myeloma; daratumumab; cytomegalovirus; Epstein-Barr virus; STEM-CELL TRANSPLANTATION; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS; PREEMPTIVE RITUXIMAB; RISK-FACTORS; REACTIVATION; RECIPIENTS; DISEASE; BORTEZOMIB; THERAPY; VIREMIA;

D O I：

10.1080/10428194.2023.2172982

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We explored the incidence of Epstein-Barr virus (EBV) and cytomegalovirus (CMV) infections in 131 patients with multiple myeloma (MM), 53 of whom received daratumumab (Dara) treatments. The Dara group had more RRMM patients than the group without Dara. CMV infection was significantly more common in patients treated with Dara (16.98%) than in patients treated with regimens without Dara (2.56%). During Dara treatments, 24.53% of patients developed CMV and/or EBV infections. Patients who developed infections had significantly lower levels of albumin and lymphocytes in their peripheral blood. The median time from the first Dara infusion to infection was 27 days. We observed NK cell depletion and T cell expansion during Dara-treatment. Patients with CMV and/or EBV infections had significantly lower numbers of NK cells, total T cells, and CD8 + T cells at 1 month, and lower numbers of CD8 + T cells at 2 months after the first Dara infusion than those without infections.

引用

页码：835 / 845

页数：11

共 57 条

[11] Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation [J].

Comoli, P. ;

Basso, S. ;

Zecca, M. ;

Pagliara, D. ;

Baldanti, F. ;

Bernardo, M. E. ;

Barberi, W. ;

Moretta, A. ;

Labirio, M. ;

Paulli, M. ;

Furione, M. ;

Maccario, R. ;

Locatelli, F. .

AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 (06) :1648-1655

[12] Rituximab Treatment for Epstein-Barr Virus DNAemia after Alternative-Donor Hematopoietic Stem Cell Transplantation [J].

Coppoletta, Stefania ;

Tedone, Elisabetta ;

Galano, Barbara ;

Soracco, Monica ;

Raiola, Anna Maria ;

Lamparelli, Teresa ;

Gualandi, Francesca ;

Bregante, Stefania ;

Ibatici, Adalberto ;

di Grazia, Carmen ;

Dominietto, Alida ;

Varaldo, Riccardo ;

Bruno, Barbara ;

Frassoni, Francesco ;

Van Lint, Maria Teresa ;

Bacigalupo, Andrea .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (06) :901-907

[13] Epidemiology, Outcome and Risk Factors Analysis of Viral Infections in Children and Adolescents Undergoing Hematopoietic Cell Transplantation: Antiviral Drugs Do Not Prevent Epstein-Barr Virus Reactivation [J].

Czyzewski, Krzysztof ;

Dziedzic, Magdalena ;

Salamonowicz, Malgorzata ;

Fraczkiewicz, Jowita ;

Zajac-Spychala, Olga ;

Zaucha-Prazmo, Agnieszka ;

Gozdzik, Jolanta ;

Galazka, Przemyslaw ;

Bartoszewicz, Natalia ;

Demidowicz, Ewa ;

Styczynski, Jan .

INFECTION AND DRUG RESISTANCE, 2019, 12 :3893-3902

[14] Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma [J].

Dimopoulos, M. A. ;

Oriol, A. ;

Nahi, H. ;

San-Miguel, J. ;

Bahlis, N. J. ;

Usmani, S. Z. ;

Rabin, N. ;

Orlowski, R. Z. ;

Komarnicki, M. ;

Suzuki, K. ;

Plesner, T. ;

Yoon, S. -S. ;

Ben Yehuda, D. ;

Richardson, P. G. ;

Goldschmidt, H. ;

Reece, D. ;

Lisby, S. ;

Khokhar, N. Z. ;

O'Rourke, L. ;

Chiu, C. ;

Qin, X. ;

Guckert, M. ;

Ahmadi, T. ;

Moreau, P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (14) :1319-1331

[15] ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4) [J].

Drgona, L. ;

Gudiol, C. ;

Lanini, S. ;

Salzberger, B. ;

Ippolito, G. ;

Mikulska, M. .

CLINICAL MICROBIOLOGY AND INFECTION, 2018, 24 :S83-S94

[16] Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA [J].

Facon, Thierry ;

Cook, Gordon ;

Usmani, Saad Z. ;

Hulin, Cyrille ;

Kumar, Shaji ;

Plesner, Torben ;

Touzeau, Cyrille ;

Bahlis, Nizar J. ;

Basu, Supratik ;

Nahi, Hareth ;

Goldschmidt, Hartmut ;

Quach, Hang ;

Mohty, Mohamad ;

Venner, Christopher P. ;

Weisel, Katja ;

Raje, Noopur ;

Hebraud, Benjamin ;

Belhadj-Merzoug, Karim ;

Benboubker, Lotfi ;

Decaux, Olivier ;

Manier, Salomon ;

Caillot, Denis ;

Ukropec, Jon ;

Pei, Huiling ;

Van Rampelbergh, Rian ;

Uhlar, Clarissa M. ;

Kobos, Rachel ;

Zweegman, Sonja .

LEUKEMIA, 2022, 36 (04) :1066-1077

[17] Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial [J].

Facon, Thierry ;

Kumar, Shaji K. ;

Plesner, Torben ;

Orlowski, Robert Z. ;

Moreau, Philippe ;

Bahlis, Nizar ;

Basu, Supratik ;

Nahi, Hareth ;

Hulin, Cyrille ;

Quach, Hang ;

Goldschmidt, Hartmut ;

O'Dwyer, Michael ;

Perrot, Aurore ;

Venner, Christopher P. ;

Weisel, Katja ;

Mace, Joseph R. ;

Raje, Noopur ;

Tiab, Mourad ;

Macro, Margaret ;

Frenzel, Laurent ;

Leleu, Xavier ;

Ahmadi, Tahamtan ;

Wang, Jianping ;

Van Rampelbergh, Rian ;

Uhlar, Clarissa M. ;

Tromp, Brenda ;

Delioukina, Maria ;

Vermeulen, Jessica ;

Usmani, Saad Z. .

LANCET ONCOLOGY, 2021, 22 (11) :1582-1596

[18] Distinct patterns of regeneration of central memory, effector memory and effector TCD8+ cell subsets after different hematopoietic cell transplant types: Possible influence in the recovery of anti-cytomegalovirus immune response and risk for its reactivation [J].

Ferrari, Valeria ;

Cacere, Camila Rodrigues ;

Machado, Clarisse Martins ;

Pannuti, Claudio Sergio ;

Dulley, Frederico Luiz ;

Barros, Jose Carlos Antonio ;

da Silva Duarte, Alberto Jose ;

Benard, Gil .

CLINICAL IMMUNOLOGY, 2006, 119 (03) :261-271

[19] Do cytomegalovirus infections affect the daratumumab treatment course in multiple myeloma patients? - Literature review [J].

Ferreira, Luana Mota ;

Cerezer, Jaderson Lima ;

Gehrcke, Mailine .

HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2021, 43 (02) :185-190

[20] Cytomegalovirus Reactivation in a Patient With Extensively Pretreated Multiple Myeloma During Daratumumab Treatment [J].

Frerichs, Kristine A. ;

Bosman, Patricia W. C. ;

Nijhof, Inger S. ;

Zweegman, Sonja ;

van de Donk, Niels W. C. T. .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (01) :E9-E11

← 1 2 3 4 5 6 →